Amlodipine Besylate/Olmesartan Medoxomil

苯磺酸氨氯地平/奥美沙坦酯

Report date: 2022/08/24 16:34:15

Base Information

Drug NameAmlodipine Besylate/Olmesartan Medoxomil
Drug Alias Nameamlodipine and olmesartan medoxomilOlmesartan Medoxomil/Amlodipine BesylateAzorCS-8663
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsVoltage-gated calcium channel blockers
TargetsAngiotensin II Receptor Type 1Voltage-gated calcium channel
Therapy Area/IndicationsEssential HypertensionHypertension
Global Approved IndicationsEssential HypertensionHypertension
Approved Indications in ChinaEssential Hypertension
Original Approved Country/TerritoryUnited States
Original Approved Date2007/09/26
Country/TerritoryUnited StatesMainland China
CombinationsYes Amlodipine BesylateOlmesartan Medoxomil
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHanmi Pharmaceutical Co LtdDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCosette Pharmaceuticals IncChina National Pharmaceutical Group Corporation Zhijun (Shenzhen) Pingshan Pharm AceuticalHarbin Gloria Pharmaceuticals Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsEssential HypertensionHypertension
Inactive IndicationsN/A

Other Information

ATC CodeC09DB02
Related LinksWikipediaKEGG